Navigation Links
Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Date:2/25/2013

689$
7,556,859Accrued expenses

7,783,4475,615,574Deferred revenue, current portion

8,891,0174,129,407Total current liabilities

18,946,15317,301,840Deferred revenue, net of current portion

34,954,96636,754,583Long-term debt, net

29,661,680-Lease financing obligation

1,450,000-Deferred rent, net of current portion

861,879802,006Stockholders' equity:Common stock

112,709103,990Additional paid-in capital

347,314,658255,817,772Accumulated deficit

(298,573,648)(245,021,646)Total stockholders' equity

48,853,71910,900,116Total Liabilities and Stockholders' Equity

$ 134,728,397$   65,758,545Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
2. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
3. Halozyme to Host Third Quarter Financial Results Conference Call
4. Halozyme Reports Second Quarter 2012 Financial Results
5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
6. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
7. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
8. Halozyme Reports First Quarter 2012 Financial Results
9. Halozyme to Host First Quarter 2012 Financial Results Conference Call
10. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
11. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  Vaccinogen, Inc. (OTC.QB: VGEN), a ... of Directors has unanimously elected Co-founder, President, Chief Executive ... to the role of Chairman of the Board. Mr. ... who resigned from the Board and his role as ... role to pursue his candidacy for the President of ...
(Date:5/5/2015)... Bio-Techne Corporation (NASDAQ: TECH ) announced ... a dividend of $0.32 per share for the quarter ... payable May 29, 2015 to all common shareholders of ... be considered by the Board of Directors on a ... ) is a global life sciences company providing innovative ...
(Date:5/5/2015)... , May 05, 2015 Research and Markets ... of the "Will Theranos Turn the Lab Industry ... Theranos has received much praise along with a healthy ... "gone public" with their potentially disruptive laboratory solution. Behind ... Has Theranos scaled microfluidic technology across a ...
Breaking Medicine Technology:Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 2Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 3Will Theranos Turn the Lab Industry Upside Down? 2
... Mass. , June 1 SynapDx Corp., a new company ... autism, announced the completion of a $9 million Series A ... Partners. , , , ... profound effect on children and their families," said Stanley N. Lapidus ...
... FRANCISCO , June 1 Prostate cancer ... FIRMAGON® (degarelix for injection) after one year of treatment ... of a Phase III extension study(1) presented here at ... used in monitoring prostate cancer patients, treatment response, and ...
Cached Medicine Technology:Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 2Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 3Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 4Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 5
(Date:5/5/2015)... On May, 5, 2015, My Positive Perspective host ... about alternatives for youngsters to do this summer. As the ... idea for starting a summer camp and how is it ... called Once Upon a Party and I come to children’s ... even scripture. We play games, sing, and dance and have ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 For the growing ... HiTemp140 series of data loggers. This data logger ... the electronic components for optimum performance throughout exposure to high ... data loggers are capable of storing up to 32,700 ... battery life of one year or longer. All data loggers ...
(Date:5/5/2015)... May 05, 2015 In the upbeat Moms ... is for moms to support each other. Parenting is ... other’s side makes it so much easier. Mothers talk ... better, feel less alone and help them realize there’s no ... Moms who are clearly dear friends share that it's ...
(Date:5/5/2015)... Buckeye Health Plan (BHP) is pleased to ... president of Buckeye Health Plan. Hill, known for growing ... Hill has more than 28 years of healthcare leadership ... managed care to large health care provider systems. Most ... of Michigan, a health plan serving the Medicaid, Medicare ...
(Date:5/5/2015)... KNOXVILLE, Tenn. (PRWEB) May 05, 2015 ... company that provides innovative interoperability solutions for hospitals ... ROI cost savings calculator. Hospital CIOs and CTOs ... at healthslide.com. The calculator shows both initial and ... offering, Boomerang. , “Our nation’s hospitals pay ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 3Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 4Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 5Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 6Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:HealthSlide Launches ROI Cost Calculator 2
... 26 Pregis Corporation, a leading international manufacturer, marketer, ... solutions, today announced its 2008 fourth quarter and full ... Company generated net sales of $219.6 million, a decrease ... the fourth quarter of 2007. Excluding incremental revenue ...
... March 26 Abusing real-time communication tools like instant ... of sales reps to engage with physicians."A lot of ... more efficient," stated a sales executive in a roundtable ... "In reality, they,re so distracted by doing four things ...
... suppresses enzyme vital to tumor growth , , THURSDAY, March 26 ... also help slow the spread of a deadly type of ... published in the current issue of the International Journal ... telomerase. Telomerase activity appears to be essential for certain tumor ...
... PLEASANTON, Calif., FRAMINGHAM, Mass. and SYDNEY, Australia, ... ), a leader in device-based mechanical circulatory support therapies ... International, Inc. (Nasdaq: HTWR ; ASX: HIN), ... today that they each received a Request for Additional ...
... Patient Health and Safety and Pharmaceutical Innovation ... Generic Pharmaceutical Association (GPhA) released the following ... Kathleen Jaeger regarding the bipartisan Senate introduction ... Life-Saving Medicine Act.""Momentum is skyrocketing for biogenerics ...
... Safeguard and Comerica Debt Facilities; Support Robust GrowthALISO VIEJO, ... CLRT ), a premier anatomic pathology and ... pharmaceutical industry, announced today that it has entered into ... Oak Investment Partners , a multi-stage venture capital ...
Cached Medicine News:Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 2Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 3Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 4Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 5Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 6Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 7Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 8Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 9Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 10Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 11Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 12Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 13Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 14Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 15Health News:Sales Force Effectiveness: Less Texting, More Engagement 2Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 2Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 3Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 4Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 5Health News:GPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act' 2Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 2Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 3Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 4Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 5Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 6Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 7Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 8
Topics include: ECG reading, ACLS (all the latest protocols and pearls), CHF, acute MI, cardiac testing, palpitations, pericarditis, arrhythmias, murmurs, athletes, valvular disease, endocarditis, sy...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
... provides leading edge information ... involving all aspects of ... on diagnosis and management ... venous disease. CVMstat® reviews ...
A Practical Approach to TEE puts detailed "how-to" information on transesophageal echocardiography (TEE) at the clinician's fingertips in the operating room, intensive care unit, office, or any other...
Medicine Products: